Clinical Trial Update: Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study [Phase 2]

View source ↗

Summary

Respira Therapeutics completed a Phase 2B trial evaluating inhaled vardenafil for pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Vardenafil inhaled (vardenafil)

Snippet

Sponsor: Respira Therapeutics, Inc. | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: COMPLETED